243 results about "Glucosidase I" patented technology

A process for the enzymatic hydrolysis of cellulose to produce a hydrolysis product comprising glucose from a pretreated lignocellulosic feedstock and enzymes for use in the process are provided. The process comprises hydrolyzing an aqueous slurry of a pretreated lignocellulosic feedstock with cellulase enzymes, one or more than one β-glucosidase enzyme and a binding agent for binding the β-glucosidase enzyme to fiber solids present in the aqueous slurry. During the hydrolysis, both the cellulase enzyme and β-glucosidase enzyme bind to the fiber solids. The hydrolysis is performed in a solids-retaining hydrolysis reactor so that unhydrolyzed fiber solids and bound enzyme are retained in the reactor longer than the aqueous phase of the slurry.

Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae.

The invention relates to a hollyhock sunflower chromocor extractive, wherein it is characterized in that: the chromocor content is 50-90%; the chromocor comprises 1. 0-5. 0% meletin-3-acacia glycoside, 8-24. 0% hyperin, 7. 0-20.0% isoquercitrin, 5. 0-15. 0% meletin-3-glucosidase, 3. 0-10.0% cotton-3-glucosidase, 0.5-5. 0% gale element, 0.5-5. 0% cotton, and 2. 0-8. 0% meletin, etc. The inventive extractive can be used to prepare the drug that treats nephritis, with high reliability.

It includes the stages of grinding the lignocellulosic biomass to a size of 15-30 mm, subjecting the product obtained to steam explosion pre-treatment at a temperature of 190-230 DEG C for between 1 and 10 minutes in a reactor (2), collecting the pre-treated material in a cyclone (3) and separating the liquid and solid fractions by filtration in a filter press (9), introducing the solid fraction in a fermentation deposit (10), adding a cellulase at a concentration of 15 UFP per gram of cellulose and 12.6 International Units of beta -glucosidase enzyme dissolved in citrate buffer pH 4.8, inoculating the fermentation deposit (10) with a culture of the heat-tolerant bacteria Kluyveromyces marxianus CECT 10875, obtained by chemical mutagenesis from strain DER-26 of Kluyveromyces marxianus and shaking the mixture for 72 hours at 42 DEG C.

Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome / Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

The invention herein encompasses methods effective to stimulate epithelial cell proliferation and / or enhance epithelial moisturization and lubrication in a mammalian subject utilizing a composition comprising one or more inhibitors of beta -glucosidase activity or beta -glucocerebrosidase activity. The composition of the method may alternatively comprise a glycosphingolipid, particularly glucocerebroside, or a combination of the above inhibitor(s) and a glycosphingolipid. The method is effective to enhance the cosmetic appearance of skin and promote healing of skin and mucous membranes damaged or deficient from aging, traumatic wounds, photo-aging and a variety of atrophic conditions. The method may be applied to cells in culture. Also included in the invention is a composition comprising one or more inhibitors of beta -glucosidase and a glycosphingolipid useful to stimulate cell proliferation and enhance tissue moisturization and lubrication.

The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I selected from one or more of betaines, lipidic betaines, betaine lipids and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, .alpha.-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.

Barley α-glucosidase is an important enzyme in the conversion of barley starch to fermentable sugars during the industrial production of ethanol, as in brewing and fuel ethanol production. The enzyme is, however, relatively thermolabile, a disadvantage for an enzyme useful in industrial processes which are preferably conducted at elevated temperatures. Site directed mutagenesis has been conducted to make mutant forms of barley α-glucosidase which have improved thermostability. The sites for this site-directed mutagenesis were selected by sequence comparisons with the sequences of other α-glucosidase proteins which are more thermostable. The recombinant mutant enzymes thus produced have been demonstrated to improve the thermostability of the enzyme.

The invention provides recombinant GH61 proteins obtained from Myceliophtora thermophila, and nucleic acids that encode such proteins. The invention also provides protein fractions isolated from M. thermophila supernatant that have GH61 protein activity. These preparations can be used to increase yield of products from reactions in which a cellulose-containing substrate undergoes saccharification by one or more cellulase enzymes, such as endoglucanase, β-glucosidase, or cellobiohydrolase. Combinations of GH61 protein and cellulases can be used to break down cellulosic biomass into fermentable sugars in the production of ethanol.

The invention discloses the weight ratio of cotton-3'-glucosidase, meletin-3'-glucosidase and isoquercitrin in total flavone extract of abelmoschus manihot. The total flavone extract of abelmoschus manihot has definite effective ingredients, more stable quality, more completed effective ingredients, better and more stable curative effect, safety and reliability, simple preparing process and low cost, is suitable for industrial production, has better effective ingredient ratio, high content and high quality and solves the problem of large dose of abelmoschus manihot.

The invention relates to a novel beta glucosidase / xylosidase difunctional cellulose degradation enzyme RuGBGX2 as well as a coding gene and application thereof. The coding sequence of amino acid of the RuGBGX2 contains 18-755th sites of an SEQ ID NO 2 sequence. The RuGBGX2 is sourced from the rumen microorganism of yak from China, a novel coding gene of the beta glucosidase / xylosidase difunctional cellulose degradation enzyme RuGBGX2 is obtained by function screening and sequencing analysis on a rumen metagenome cosmid library and a subclone library. The beta glucosidase / xylosidase difunctional cellulose degradation enzyme provided by the invention can be widely applied to the degradation of cellulose and the fields such as cellulose biotransformation, chemical industry, spinning, foods, bioenergy, feed additives, medical industry and the like. By utilizing the difunctional enzyme RuGBGX2 to degrade wood fiber, the varieties of added enzymes can be reduced, and an enzymolysis process can be simplified.

The invention discloses a white mulberry root-bark exact with the glucosidase inhibition function, a preparation method thereof and a quality control method. During the preparation of the white mulberry root-bark extract, extraction, concentration and centrifugalization are adopted, and the methods of three different types of anion-cation exchange resin columns, drying and so on are carried out to fully extract and highly concentrate the effective drugs; at the same time, the invention further provides the quality control method for carrying out the content measurement of the extract.

The invention discloses a vaginitis test kit which comprises a reaction device, a sampling test tube, a straw, joint test diluent, joint test chromogenic reagent, joint test stop solution, a user manual and a joint test colourimetric card, wherein a hydrogen peroxide reaction hole, a leukocyte esterase reaction hole, a sialic acid glucoside enzyme reaction hole, a beta- glucuronic acid enzyme reaction hole, a P glucosidase reation hole and a pH value hole; relevant reaction bases are arranged in the reaction holes; reach reaction base comprises a corresponding reaction substrate curing layer,a chromogenic promotional layer and a chemical inert carrier layer. The invention also provides a preparation method of the test kit and the preparation method of a novel chemical carrier. The test kit can be used for distinguishing bacterial vaginosis and vaginitis, and can further identify aerobic / anaerobic bacteria, facultative anaerobic bacteria and other flora in vaginal secretion. The method is simple and quick to operate, has high accuracy, and is applicable to clinical practice, particularly hospital outpatient practice.

The present invention provides compositions and methods for the expression of recombinant β-glucosidase variants, as well as their use in the production of fermentable sugars from cellulosic biomass.

The invention relates to a beta-glucosidase and an application thereof, wherein the beta-glucosidase comprises: a, enzyme with the sequence of SEQ ID NO:1; and b, enzyme which is derived from the enzyme in step a through substituting, deleting or adding one or a plurality of amino acids and has the activity of the enzyme in the step a. The selected beta-glucosidase provided by the invention has the deoxyglucose and hygromycin resistance and transglycosylation, under the transglycosylation, cellobiose and other oligosaccharides can generate sophorose and other inductors, and enter cells through a constitution permease system on a cell membrane, and the synthesis of cellulose in the cells is initiated. Consequently, the beta-glucosidase can be used for the production of catalytically synthesizing the sophorose to induce the cellulose, and thereby having a greater commercial value.

The invention provides a method for preparing salidroside with an enzymatic method. The method includes the specific steps that deep-eutectic solvents (DESs) synthesized by heating and stirring choline chloride and glycerin serve as reaction solvents, and the reaction solvents are biologically catalyzed and glycosylated into salidroside through beta-D-glucosidase, wherein the conversion rate of a substrate can be 30% or above (by glucose). According to the method, the adopted DESs are green and nontoxic, the solubility of the reaction substrate is high, and good biocompatibility is achieved. The preparing method has the advantages of being easy to operate, efficient, environmentally friendly, mild in condition, low in cost and the like.

The invention relates to a producing process of the inulin and the oligo fructose produced from the fruit of the snow lotus. The process is mainly that the fresh fruit of the snow lotus is cleaned, chipped, expressed juice, filtrated, dried, crushed characterized in that the slicing is dipped into the color fixative 1-3 hour and the inulin is purified by adding the 10% confected inulinase and the water and is fermented 48-72 hour in the aerobic atmosphere of the temperature of 20-30. The snow lotus inulin and the glucosidase fructose can be used for the health products, the food additive.The using of it as the health products has many merits of the low consumption of taking medicine, the good curative effect, taking conveniently, transporting and storing conveniently. So it can be added into the food such as the drink, the cake and the candy to form the functional food. The invention has some merits of the advance arts and crafts, the high quality.

The invention discloses a preparation method of brown ginseng, which comprises the following steps of: hydrolyzing the crude raw materials of fresh ginseng, sun-dried ginseng, red ginseng, ginseng stems, ginseng leaves, ginseng flowers, ginseng fruits and the like by beta-D-glucosidase, conducting high-temperature steam treatment under appropriate heating temperature and time conditions, and heating and drying to obtain the ginseng product. The ginseng product prepared by using the preparation method has the advantages of high content of rare saponin, less loss of total saponin, complete product configuration and the like, and meanwhile, the method has simple process, high efficiency and low cost.

Disclosed is a method and composition for nutritional compositions containing glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome / Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

The present invention provides compositions comprising a cellulolytic bacterium and an isolated BETA-glucosidase enzyme or comprising cellulolytic bacterium that expresses a secreted recombinant BETA-glucosidase enzyme, and methods of using same for hydrolysis of cellulose and cellulosic feedstocks.

The invention relates to a making method of flavouring agent of fresh-cut rose and usage of the flavouring agent based on the fresh-cut rose with beautiful color and slight scent, which is characterized by the following: using beta-glycosides as the flavouring agent to synthesize aromatic substance through chemical method to add in water-based according to a proper density; absorbing the beta-glucosidase accompanied by absorption of water and nutrient into the fresh-cut rose; releasing the natural scent of rose and fruit of the aromatic substance to make the fresh-cut rose with fragrant flavour after hydrolyzing the beta-glycosides partially under effect of fresh flower endogenous glucosidase. The invention extends the life of bottle flower by addition of amylaceum of the fresh flower because of producing a large amount amylaceum after hydrolytic decomposition of the beta-glycosides, which displays characters of holding and extending the vital force of the fresh-cut rose.

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.

The present invention relates to a method for providing alpha -glucosidase inhibition to a subject by administering a pharmaceutical composition comprising a alpha -glucosidase inhibitory agent selected from pipataline (formula 1a), sesamin (formula 1b), pellitorine (Formula 1c), guineensine (Formula 1d) and brachystamide-B (formula 1e) having therapeutic application for diabetes mellitus, cancer, viral diseases such as hepatitis B and C, HIV, AIDS etc; also the invention provides a process for the isolation of said alpha -glucosidase inhibitory agent from the plant source Piper longum in significant yields.

The present invention provides a method for increasing the activity of a mutant or wild-type a-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1- deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The 1-deoxynojirimycin derivative is substituted at the N or Cl position. Combination therapy with replacement a-glucosidase gene or enzyme is also provided.

Efficient, selective, and economical methods for producing non-dairy ready-to-use milk substitute cereal dispersions having intact beta-glucans, proteins, and natural sugars, while retaining the aroma and flavor of natural cereal. The methods include treating a cereal substrate suspension with an enzyme preparation that comprises at least one hydrolase having the ability to hydrolyze alpha-glycosidic bonds and having no glucanase and proteinase effect. The hydrolase may be selected from the group consisting of beta-amylase, alpha-amylase, amyloglucosidase and pullulanase, with the proviso that when the enzyme preparation comprises alpha-amylase or beta-amylase, there is always a mixture of at least one other of the alpha-glycosidic hydrolases. When beta-amylase and alpha-amylase are selected, they are used as a mixture, i.e., introduced simultaneously, to provide for accelerated enzymatic hydrolysis and for reduced amounts of the enzymes than otherwise needed if the enzymes were used separately. In addition to the above-identified hydrolases, the enzyme preparations of the present invention may further comprise an isomerase, such as glucose isomerase.

The invention relates to a process for preparing alpha- glucosidase depressant from Cinnamomum cassia, which comprises removing low-polarity constituents with no inhibiting activity to alpha-glucosidase from Cinnamomum cassia by means of fluid extraction technique, and carrying out solid-liquid oscillation extraction to the residual of extracting with anhydrous alcohol. The extracted effective portion has rather strong inhibiting activity to alpha-glucosidase.